https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL

Ibrutinib–Venetoclax Outperforms Ibrutinib Alone and FCR in Long-Term CLL

Ibrutinib combined with venetoclax significantly improved measurable residual disease and progression-free survival in patients with chronic lymphocytic leukemia.

administrator

Related Articles